Paper Details

  1. Home
  2. Paper Details

Arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) as a maintenance therapy for adult T cell leukemia/lymphoma.

Author: AsnafiVahid, Avettand-FenoelVéronique, BanghamCharles R M, BazarbachiAli, CheminantMorgane, CookLucy, DelarueRichard, FrenzelLaurent, HermineOlivier, MarçaisAmbroise, SibonDavid, SuarezFelipe, WitkoverAviva, de ThéHugues

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Adult T-cell leukemia-lymphoma (ATL) is an aggressive cancer with a poor prognosis. Arsenic trioxide (As2O3) has shown promise as a targeted therapy for ATL in a mouse model, potentially offering a new treatment option for this disease.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND">Adult T-cell leukemia-lymphoma (ATL) is an aggressive mature lymphoid proliferation associated with poor prognosis. Standard of care includes chemotherapy and/or the combination of zidovudine and interferon-alpha. However, most patients experience relapse less than 6 months after ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085150/

データ提供：米国国立医学図書館（NLM）

Arsenic Trioxide: A Potential Weapon Against Adult T-cell Leukemia/Lymphoma

The fight against [adult T-cell leukemia-lymphoma (ATL)] is a challenging one, with limited treatment options and a poor prognosis for many patients. This study explores the potential of [arsenic trioxide (As2O3)] as a [maintenance therapy] for ATL, building upon previous research demonstrating its ability to target [ATL leukemia initiating cells].

Arsenic Trioxide: A New Hope for ATL Patients

The study highlights the need for more effective treatment options for ATL, particularly in the context of [relapse] after initial therapy. Arsenic trioxide has emerged as a promising candidate for [maintenance therapy], targeting the [leukemia initiating cells] that contribute to disease recurrence. Further research is needed to fully assess its effectiveness and safety in clinical settings.

A Journey Toward Cure: Exploring New Therapies for ATL

The study's findings provide hope for ATL patients, offering a potential new avenue for [maintenance therapy] that could help extend remission durations and improve overall survival. Continued research is crucial to further explore the efficacy and safety of arsenic trioxide in ATL treatment, ultimately leading to more effective and personalized therapies for this aggressive cancer.

Dr.Camel's Conclusion

Just as the desert holds hidden oases of hope, researchers are constantly seeking new therapies for challenging diseases like ATL. This study offers a glimpse into the potential of arsenic trioxide as a maintenance therapy, reminding us that the quest for effective treatments continues, fueled by the unwavering pursuit of better outcomes for patients.

Date :
  1. Date Completed 2021-03-10
  2. Date Revised 2021-03-10
Further Info :

Pubmed ID

32199462

DOI: Digital Object Identifier

PMC7085150

Related Literature

Article Analysis
・Side Effects of azt
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.